An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions
Open accessThe DOI matches its Crossref record; 47 of the 51 references it cites were found in a registry or an index; 2 of the 33 sources its claims cite were checked for support.
Abstract
BACKGROUND: Although originally marketed as safe alternatives to the habit-forming benzodiazepines, growing numbers of zaleplon, zolpidem, and zopiclone ("Z-drugs") clinical concerns relating to their potential of abuse, dependence, and withdrawal have been reported over time. We aimed here at assessing these issues analyzing datasets of adverse drug reactions provided by the European Medicines Agency through the EudraVigilance system. METHODS: Analyzing the adverse drug reactions databases of each Z-drug, descriptive analyses have been performed on cases and proportional reporting ratios (PRRs) computed. RESULTS: An overall number of 33 240 (e.g., 23 420 zolpidem; 9283 zopiclone; and 537 zaleplon) misuse-, abuse-, dependence-, and withdrawal-related adverse drug reactions, corresponding to some 6246 unique patients given Z-drugs, were here identified. Cases were studied and described, including demographic characteristics and clinical data such as concomitant drugs, doses, routes of administration, and outcomes of the reactions (being fatalities recorded). Considering PRR values and in comparison with zopiclone, zolpidem was more frequently involved in both misuse/abuse and withdrawal issues. Zolpidem and zopiclone presented with the same dependence risk, but zopiclone was most involved in overdose adverse drug reactions. Compared with zaleplon, zopiclone presented higher dependence and overdose-related issues but slightly lower misuse/abuse and withdrawal PRR values. CONCLUSION: Current data may only represent a gross underestimate of the real prevalence of Z-drug misuse. Caution should be exercised when prescribing those molecules, especially for patients with psychiatric illnesses and/or history of drug abuse. We recommend the need to invest in proactive pharmacovigilance activities to better and promptly detect, understand, and prevent any possible misuse potential of prescribed medications.
Overview
CoChat Summary
## TL;DR
This pharmacovigilance study mined the EMA EudraVigilance database for Z-drug misuse, abuse, dependence, and withdrawal reports and found substantial reporting across zolpidem, zopiclone, and zaleplon. The authors conclude these data likely underestimate real-world misuse and support caution, especially in patients with psychiatric illness or a history of drug abuse.
## Key findings
- The database search identified 33,240 misuse/abuse/dependence/withdrawal-related adverse drug reactions (ADRs), corresponding to 6,246 unique patients using Z-drugs.
- By drug, the identified ADRs were 23,420 zolpidem, 9,283 zopiclone, and 537 zaleplon.
- Compared with zopiclone, zolpidem was reported more often for misuse/abuse and withdrawal; zolpidem and zopiclone had the same dependence risk; and zopiclone was more involved in overdose ADRs.
- Reported fatal outcomes were highest for zolpidem (20.3%), compared with zopiclone (9.33%) and zaleplon (1.1%). In the text, zaleplon is described as the comparatively least misused / lower-risk Z-drug.
## Methods
- The study used a descriptive pharmacovigilance analysis of EMA EudraVigilance individual case safety reports for Z-drug-related misuse, abuse, dependence, and withdrawal.
- The author requested all relevant reports using MedDRA preferred terms and Standardised MedDRA Queries related to drug abuse/dependence/withdrawal; the analysis covered 2003 to 2017 for zaleplon, 206,315 zolpidem ADRs, and 65,140 zopiclone ADRs as the drug-specific source pools reported in the text.
- Analyses included descriptive summaries and proportional reporting ratios (PRRs) comparing drugs on misuse/abuse, dependence, withdrawal, and overdose reporting.
## Limitations
- The paper states the data likely underestimate the real prevalence of Z-drug misuse because reporting is voluntary and depends on clinician awareness, drug availability, and extent of use.
- The authors note that reports had missing data (for example, dosages ingested and background diagnosis), and that duplicate reports were possible, although they tried to mitigate this with unique case codes.
- Evident from the text: the study uses suspected ADR reports, so the reports do not prove causality between a Z-drug and the event, and the database lacks a reliable denominator for actual exposure/availability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 0 Not valid · 16 Not checked · 34 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This confirms previous findings, suggesting increasing levels of suicidal ideation, suicide attempts, and suicide risk in patients administered with Z-drugs (Brower et al., 2011; MCCall et al., 2017).”
§ An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions > Discussion To the best of our understanding, this paper is the first to provide uniquely systematic data in terms of identification and analysis of zolpidem, zopiclone, and zaleplon misuse, abuse, dependence, and withdrawal issues. The present data were extracted from a high-quality, large-scale, pharmacovigilance database such as the EMA’s EV. Together with the World Health Organization’s Drug Monitoring Program, the EV database is considered a worldwide reference standard (Schifano and Chiappini, 2018). Most literature papers, so far, were based on small case series/single case studies (Aranko et al., 1991; Sikdar and Ruben, 1996; Rooney and O’Conner, 1998; Wong et al., 2005; Flynn and Cox, 2006; Chiaro et al., 2018). Conversely, current findings referred to overall much larger (e.g., 33 240 ADRs; corresponding to some 6246 unique cases) numbers of patients presenting with Z-drug misuse issues. Indeed, current data may represent only a gross underestimate of the Z-drug misuse issues’ real prevalence. In fact, reports were here submitted spontaneously, and levels of misperception that these drugs are safe, which could prevent professionals from reporting, may still be identified (Medsafe, 1998). The analyses of the EV databases confirmed the diversion potential and the possibility of abuse, misuse, dependence, and withdrawal issues related to all Z-drugs (zaleplon, zopiclone, and zolpidem), albeit some differences have emerged within this group. Compared with zaleplon, the misuse/abuse issues seemed here to be lower for zopiclone and zolpidem. Conversely, compared with zopiclone, zolpidem emerged as being more frequently related to misuse or abuse and withdrawal reports; if compared with zaleplon, zolpidem was more frequently related to dependence and overdose reports. Among Z-drugs, zolpidem was the most frequently reported in the EV dataset, being associated with intravenous administration, very high dosage consumption, and concomitant use of recreational drugs. These data are consistent with previous suggestions (Griffiths and Johnson, 2005; Rousselet et al., 2017) and recent reports based on both zolpidem-related falsified prescription rates in France (Jouanjus et al., 2018) and clinical dependence issue data from an Indian tertiary care center (Shukla et al., 2017). Overall, zaleplon ADRs were numerically lower than zopiclone- and zolpidem-related ADRs and less frequently associated with both idiosyncratic/atypical ways of administration and concomitant recreational drug intake. Hence, one could tentatively identify in zaleplon the relatively (Desousa, 2009; Paparrigopulos et al., 2008) “most safe” Z-drug. A full comparison among Z-drugs should, however, consider as well the precise worldwide prescription figures, which could serve as a proper denominator. Indeed, within the Z-drug group, one could argue that zaleplon may present with the lowest availability levels due to its higher purchase costs (NICE, 2004). Regarding zopiclone use, Jaffe et al. (2004) assessed its use among 297 drug addicts who had been consecutively admitted to addiction treatment centers in the United Kingdom. It emerged that more than half had used zopiclone, which ranked fourth after diazepam, temazepam, and nitrazepam. About 80% of zopiclone users had obtained the drug through a prescription, but 42% reported having purchased it on the streets (Jaffe et al., 2004). Analyzing the misuse patterns of benzodiazepine and Z-drug users, Kapil et al. reported that 29.6% had ever misused them, with 40.5% of individuals misusing at least 2 of these medications. Diazepam (53.4%) and zopiclone (24.1%) were the most frequently reported medications, with decreasing numbers of individuals misusing lorazepam (22.4%), alprazolam (17.2%), zaleplon (11.2%), nitrazepam (10.3%), phenazepam (7.8%), and zolpidem (5.2%). Moreover, iUsing data from a health insurance reimbursement database, which collects information from 77% of the French population, Ponté et al. (2018) assessed the extent and risk of opioid analgesic abuse related to benzodiazepines and hypnotics; they considered both the molecules’ Doctor Shopping Quantity (intended to assess the extent of abuse) and the Doctor Shopping Index (DSI; intended to identify a signal of abuse). Interestingly, they found that the Doctor Shopping Quantity of anxiolytics and hypnotics (influenced by their large availability levels) was 10 times higher than that of opioids. Conversely, the DSI of opioids (2.79%) was higher than that of both hypnotics (2.06%) and anxiolytics (1.81%). Among benzodiazepines, flunitrazepam and zolpidem presented with the highest DSI values (13.2% and 2.2%, respectively) (Ponté et al., 2018). Overall, higher levels of physical and compulsive signs of dependence with zolpidem, rather than with zopiclone (Griffiths and Johnson, 2005; Rousselet et al., 2017; Ponté et al., 2018), have been described. Current Z-drug data are consistent with the new trends in prescription drug misuse (Throckmorton et al., 2018), which is at times occurring within the context of the rising levels of novel psychoactive substances misuse (Schifano et al., 2018). It is, however, concerning that a range of other prescription and recreational psychotropics were here identified in combination with Z-drugs, including antidepressants, benzodiazepines, antipsychotics, other Z-drugs, opiates/opioids, alcohol, cannabis, cocaine, methamphetamine, and ketamine. The present data may support previous hypotheses, for example, that there may be 2 subsets of individuals misusing Z-drugs; the first group may include patients with psychiatric comorbidities (Zammit, 2009; Lin et al., 2017), who were originally started with these molecules for insomnia but who developed tolerance and withdrawal phenomena, therefore requiring increasing dosages overtime (Griffiths and Johnson, 2005); and the second population may include young people, who are ingesting large Z-drug dosages in combination with other recreational compounds and through idiosyncratic intake modalities (Sikdar and Ruben, 1996; Ayonrinde and Sampson, 1998; Rooney and O’Conner, 1998; Hajak, 1999; Johansson et al., 2003), which can increase the drug bioavailability levels (Victorri-Vigneau et al., 2007) and hence facilitate achieving better euphoria. Fatalities were here reported for all Z-drugs, although this typically occurred mostly with zolpidem and zopiclone, both typically ingested in a poly-drug misuse scenario, thus confirming previous reports (Garnier et al., 1994; Casula et al., 2013; Gunja, 2013). The comparatively low levels of zaleplon toxicity/fatalities here identified could, however, be associated with the molecule’s ultra-short half-life and rapid antemortem metabolism, which can affect its detection (Gunja, 2013). Mortality from Z-drugs may be similar to that of benzodiazepines (Garnier et al., 1994; Reith et al., 2003). A UK study on zopiclone-related deaths (Buckley and McManus, 2004) found that the zopiclone fatal toxicity index was similar to that of zolpidem but lower compared with flurazepam, flunitrazepam, temazepam, triazolam, and nitrazepam. It is of interest to note that a number of suicidal behavior-related ADRs (e.g., suicide attempts, suicidal ideation) were here identified, and especially so for both zolpidem and zopiclone. This confirms previous findings, suggesting increasing levels of suicidal ideation, suicide attempts, and suicide risk in patients administered with Z-drugs (Brower et al., 2011; MCCall et al., 2017).
What the sources say
- Not checked yetcites Brower et al., 2011
- Supportedcites MCCall et al., 2017 matched to “Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA” (2017) source
The Abstract Results state that 'the epidemiological studies show that hypnotics are associated with increased risk for suicide,' and the Z-drug-specific material in our copy reports elevated ideation, attempts and deaths: the FDA 2006 post-marketing review counted 49 zolpidem suicide-related events (suicidal ideation n=12, attempt/self-harm n=16, suicide deaths n=21) plus comparable eszopiclone and zaleplon figures (Results, Illustrative Cases), a Taiwanese register giving an adjusted OR of 2.08 (1.83-2.36) for zolpidem exposure (Results, Retrospective Cohort Studies), and an Australian reporting compilation giving OR 8.3 (5.4-12.8) for zolpidem-related suicidality. The same section also reports the Brower NCS-R odds ratios (2.2 ideation, 1.9 plan, 3.4 attempt) for hypnotic users, so the hedged 'suggesting increased levels' is within the source. Two caveats our copy attaches, which the citing sentence's hedge does not contradict: the Introduction notes that on prior reviews and surveys 'the link between sedative/hypnotics and suicidality appears to be uncertain,' and the Abstract notes none of the epidemiologic studies adequately controlled for depression or other psychiatric disorders; the evidence is naturalistic exposure rather than drug administration under observation. (LLM, conf=0.82)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the total number of ADRs (65 140), those relating to misuse-abuse-dependence-withdrawal issues and judged by the reporter as “suspect” were 9283 (14.25%) (Table 1)”
§ An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions > Results > Zopiclone ADRs As for zaleplon and zolpidem, most zopiclone-related ADRs were reported by physicians from non-EEA countries (45.8%), with pharmaceutical companies having been the most typical (51.4%) reporting agencies. Of the total number of ADRs (65 140), those relating to misuse-abuse-dependence-withdrawal issues and judged by the reporter as “suspect” were 9283 (14.25%) (Table 1), with the most represented ADRs including: “intentional overdose” (29.9%), “overdose” (23.1%), and “drug use disorder” (23.1%). Typically, these ADRs involved adult (18–64 years old) females. A lone zopiclone ingestion was reported in 416/1760 (23.6%) cases; as for zaleplon and zolpidem, a concomitant use of prescription drugs was reported, mostly involving benzodiazepines in 891/4374 (20.4%) cases, antidepressants in 658/4374 (15.0%) cases, antipsychotics in 475/4374 (10.9%) cases, and opiates/opioids in 131/4374 cases (2.99%). Moreover, a range of recreational drugs was identified (e.g., cannabis in 12 cases, cocaine in 6 cases, methamphetamines in 1 case), and intravenous and subcutaneous intake modalities were reported as well. Finally, as for zolpidem, a range of suicidal behavior-related ADRs was reported, including “intentional self-injury” (111/9283:1.2%), “suicidal behavior” (43/9283: 0.5%), and “suicide attempt” (2526/9283: 27.2%). When dosages were reported, levels in excess of 15 mg were described in 577 (360 individuals) of zopiclone cases, including 205 ADRs (120 cases) where the dosage ingested was in the 450- to 2250-mg range.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 3 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the total number of zolpidem ADRs (206 315), those relating to misuse-abuse-dependence-withdrawal issues and judged by the reporter as “suspect” were 23 420 (11.35%) (Table 1).”
§ An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions > Results > Zolpidem ADRs Of the total number of zolpidem ADRs (206 315), those relating to misuse-abuse-dependence-withdrawal issues and judged by the reporter as “suspect” were 23 420 (11.35%) (Table 1). Most ADRs were reported by physicians from non-EEA countries (49.7%), pharmaceutical companies having been the most typical (41.3%) reporting agencies. “Drug use disorder” (40.0%), “overdose” (23.7%), and “intentional overdose” (16.7%) were the most represented ADRs. Typically, these ADRs involved adult (18–64 years old) females. A lone Z-drug ingestion was reported in 1856/4374 (42.4%) zolpidem cases, while a concomitant use of prescription drugs was reported, mostly involving antidepressants (26.6%), benzodiazepines (19.0%), and opiates/opioids (14.2%). Moreover, a range of recreational drugs was identified, specifically alcohol (174 cases), cocaine (30 cases), amphetamines (21 cases), and cannabis (13 cases). Atypical intravenous (22 cases), nasal (5 cases), and sublingual (1 case) intake modalities were here reported for zolpidem. Dosages were higher than 20 mg in 7371 ADRs, in 6234 of these cases, the dosage was above 100 mg, and in 20 ADRs (7 cases) it was in excess of 2000 mg. Finally, a range of suicidal behavior-related ADRs was reported for zolpidem, including “intentional self-injury” (102/23 420: 0.5%), “suicidal behavior” (44/23 420: 0.2%), and “suicide attempt” (3101/23 420: 13.2%). The rates of ADRs with a fatal outcome were higher for zolpidem (20.3%) compared with both zopiclone (9.33%) and zaleplon (1.1%).
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 3 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared with zaleplon, zopiclone presented higher dependence and overdose-related issues but slightly lower misuse/abuse and withdrawal PRR values.”
§ An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared with zaleplon, zopiclone presented higher dependence and overdose-related issues but slightly lower misuse/abuse and withdrawal PRR values.”
§ An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
28 more claims
Create a free account to see all 52 claims and to verify the 31 references still open.
- It may state two separate claims as one. 12
- Probably not a substantial claim. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Although there are a few hundreds of exotic BDZ discussed within the NPS community (28), a non-participant, multilingual, qualitative/netnographic study recently focused on those 29 exotic BDZ which have been formally identified as NPS by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (26).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In their pharmacovigilance analysis, Schifano et al. 9 identified 9,283 reports of suspected adverse reactions linked to inappropriate use, abuse, dependence, or withdrawal related to zopiclone; among these, 23.1% were classified as substance use disorder , with isolated use of zopiclone reported in 23.6% of the cases.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of Z-drug use disorder may be higher in women, though the findings are inconsistent across studies.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In France, 9 23,420 adverse-event reports were associated with its inappropriate use, with 40% classified as substance use disorder and 13.2% involving suicide attempts; zolpidem was the only substance implicated in 42.4% of the reports, and its fatality rate (of 20.3%) surpassed that of zopiclone and zaleplon.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence 3 9 38 suggests that pharmacodynamic factors—such as selectivity for specific GABA A receptor subunits—and pharmacokinetic parameters—such as half-life and absorption rate—play a crucial role in determining the risk of dependence, withdrawal, and adverse effects associated with these agents.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Finally, a range of suicidal behavior-related ADRs was reported for zolpidem, including “intentional self-injury” (102/23 420: 0.5%), “suicidal behavior” (44/23 420: 0.2%), and “suicide attempt” (3101/23 420: 13.2%).”
§ An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions > Results > Zolpidem ADRs
Reported 0.5 · recomputed 0.435525
Citations
Cites
Sota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M. C., Lopalco, G., La Torre, F., Fabiani, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01526 · Cited by 616
Hajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00491.x · Cited by 404
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Griffiths, R. R., & Johnson, M. W. (2005) · PubMed · Cited by 260
Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.
(2018) · Europe PMC (PubMed Central) · Cited by 250
The clinical and forensic toxicology of Z-drugs
Gunja, N. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0292-0 · Cited by 230 · cited 7×
“Fatalities were here reported for all Z-drugs, although this typically occurred mostly with zolpidem and zopiclone, both typically ingested in a poly-drug misuse scenario, thus confirming previous reports (Garnier et al., 1994; Casula et al., 2013; Gunja, 2013).”
InfluentialHajak, G. (1999) · Drug Safety · doi:10.2165/00002018-199921060-00003 · Cited by 213 · cited 4×
“, 2017), who were originally started with these molecules for insomnia but who developed tolerance and withdrawal phenomena, therefore requiring increasing dosages overtime (Griffiths and Johnson, 2005); and the second population may include young people, who are ingesting large Z-drug dosages in combination with othe…”
InfluentialVictorri‐Vigneau, C., Dailly, E., Veyrac, G., & Jolliet, P. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02861.x · Cited by 201 · cited 3×
“, injecting) or the intake of high dosages may well increase the risk of Z-drug abuse (Victorri-Vigneau et al., 2007).”
InfluentialTreating insomnia: Current and investigational pharmacological approaches
Ebert, B., Wafford, K. A., & Deacon, S. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.014 · Cited by 166
Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics
Nutt, D. J., & Stahl, S. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106927 · Cited by 163 · cited 1×
“Z-drugs are GABA-A receptor modulators chemically unrelated to benzodiazepines approved for the short-term management of insomnia disorders (NICE, 2004) due to their hypnotic effects by reducing sleep latency and improving sleep quality (Nutt and Stahl, 2010).”
Research works printed but not linked: 3
- Casula, 2013, UK deaths associated with ‘Z’ drugs (Zopiclone, Zolpidem & Zaleplon) in Z-drugs: a review of the evidence of misuse and harm, 19
- Desousa, 2009, Zaleplon abuse, JPPS, 5, 31
- Medical Dictionary for Regulatory Activities (MedDRA), 2018, Introductory guide for Standardised MedDRA Queries (SMQs) Version 21.0
Cited by
New/emerging psychoactive substances and associated psychopathological consequences
Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. (2021) · Psychological Medicine · doi:10.1017/s0033291719001727 · Cited by 119
Self-citationYue, J.-L., Chang, X.-W., Zheng, J.-W., Shi, L., Xiang, Y., Que, J., Yuan, K., Teng, T., Teng, T., Li, Y., et al. (2023) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2023.101746 · Cited by 137
Fatigue in Aviation: Safety Risks, Preventive Strategies and Pharmacological Interventions
Wingelaar-Jagt, Y. Q., Wingelaar, T. T., Riedel, W. J., & Ramaekers, J. G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.712628 · Cited by 139
“A recent study showed that only 3.5% of aircrew members experienced side effects during a ground test, with next-day drowsiness and headaches being the side effects most often reported (Sen Kew and See, 2018).”
BackgroundInfluentialNon-pharmacological Approaches for Management of Insomnia
Chan, N. Y., Chan, J. W. Y., Li, S. X., & Wing, Y. K. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01029-2 · Cited by 135
Zolpidem: Efficacy and Side Effects for Insomnia
Edinoff, A. N., Wu, N. W., Ghaffar, Y. T., Prejean, R., Gremillion, R., Cogburn, M., Chami, A. A., Kaye, A. M., & Kaye, A. D. (2021) · Health Psychology Research · doi:10.52965/001c.24927 · Cited by 129
Roch, C., Bergamini, G., Steiner, M. A., & Clozel, M. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05954-0 · Cited by 86
Benzodiazepines and Related Sedatives
Peng, L., Morford, K. L., & Levander, X. A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.012 · Cited by 86
Begum, M., González‐Chica, D. A., Bernardo, C., Woods, A., & Stocks, N. P. (2021) · British Journal of General Practice · doi:10.3399/bjgp.2021.0054 · Cited by 63
Sex and Gender Differences in the Effects of Novel Psychoactive Substances
Fattore, L., Marti, M., Mostallino, R., & Castelli, M. P. (2020) · Brain Sciences · doi:10.3390/brainsci10090606 · Cited by 78
Scharner, V., Hasieber, L., Sönnichsen, A. C., & Mann, E. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-02757-6 · Cited by 78
“An examination of 33,240 reports of suspected adverse drug reactions to the European Medicines Agency between 2003 and 2017 established a great risk of dependence as well as a massive potential for abuse with the authors estimating that current data potentially starkly underestimate the real prevalence of BDLM misuse…”
BackgroundCarter, S. G., & Eckert, D. J. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101492 · Cited by 72
Meaadi, J., Obara, I., Eldabe, S. S., & Nazar, H. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01528-y · Cited by 78
Palagini, L., & Bianchini, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.893015 · Cited by 53
Chiappini, S., Schifano, F., Corkery, J., & Guirguis, A. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959615 · Cited by 47
Self-citationWirth, M. D., Jessup, A., Turner‐McGrievy, G. M., Shivappa, N., Hurley, T. G., & Hébert, J. R. (2020) · SLEEP · doi:10.1093/sleep/zsaa093 · Cited by 44
“Additionally, many of these medications can be habit forming [13].”
BackgroundNonmedical use of benzodiazepines and Z‐drugs in the UK
Hockenhull, J., Black, J. C., Haynes, C. M., Rockhill, K. M., Dargan, P. I., Dart, R. C., & Wood, D. M. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14397 · Cited by 38
Pregabalin Abuse in Combination With Other Drugs: Monitoring Among Methadone Patients
Lancia, M., Gambelunghe, A., Gili, A., Bacci, M., Aroni, K., & Gambelunghe, C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.01022 · Cited by 39
“In cases of off-label PGB use to manage bipolar disorder, alcohol/narcotic withdrawal states, and ADHD, there may be a relatively greater risk of misuse.”
BackgroundInfluentialChiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020) · Brain Sciences · doi:10.3390/brainsci10020105 · Cited by 33
“, pharmacist, physician); outcomes (fatal, recovered, resolved); clozapine dosage; possible concomitant drug(s); and diagnosis/reporter’s comments, if recorded [37].”
Self-citationUse of hypnotic drugs among children, adolescents, and young adults in Scandinavia
Wesselhoeft, R. T., Rasmussen, L., Jensen, P. B., Jennum, P., Skurtveit, S. O., Hartz, I., Reutfors, J., Damkier, P., Bliddal, M., & Pottegård, A. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13329 · Cited by 37
Wang, J., Zhao, H., Shi, K., & Wang, M. (2023) · Medicine · doi:10.1097/md.0000000000033213 · Cited by 32
“[27] Owing to the limitations of medication use, including potential dependence and resistance to long-term use,[50] and the recognition of excessive anxiety factors in the insomnia trajectory, non-pharmacological approaches and traditional Chinese medicine treatments have received increasing attention in the last 2 d…”
BackgroundChan, A. Y. L., Gao, L., Howard, L. M., Simonoff, E. A., Coghill, D., Ip, P., Lau, W. C. Y., Taxis, K., Wong, I. C. K., & Man, K. K. C. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000529141 · Cited by 35
Ramelteon modulates gamma oscillations in the rat primary motor cortex during non-REM sleep
Yoshimoto, A., Yamashiro, K., Suzuki, T., Ikegaya, Y., & Matsumoto, N. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.11.006 · Cited by 30
Rosenqvist, T. W., Wium‐Andersen, M. K., Wium‐Andersen, I. K., Jørgensen, M. B., & Osler, M. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230075 · Cited by 40
Fornaro, M., Caiazza, C., Simone, G. D., Rossano, F., & de Bartolomeis, A. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.11.033 · Cited by 30
Moline, M. L., Asakura, S., Beuckmann, C. T., Landry, I. S., Setnik, B., Ashworth, J., & Henningfield, J. E. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06320-y · Cited by 25
“Similarly, based on an examination of drug abuse–related adverse drug reactions in the European Medicines Agency Database, ZOL was also the most frequently misused/abused Z-drug in Europe (Schifano et al. 2019).”
BackgroundZhao, F.-Y., Xu, P., Kennedy, G. A., Conduit, R., Zhang, W., Wang, Y., Fu, Q.-Q., & Zheng, Z. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1157419 · Cited by 34
BDZs, Designer BDZs and Z-drugs: Pharmacology and Misuse Insights
Zaami, S., Graziano, S., Tittarelli, R., Beck, R., & Marinelli, E. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210917145636 · Cited by 27
Istvan, M., Caillet, P., Rousselet, M., Guerlais, M., Laforgue, E., Gérardin, M., Jolliet, P., Feuillet, F., & Victorri‐Vigneau, C. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14753 · Cited by 31
Lalovic, B. B., Majid, O., Aluri, J., Landry, I. S., Moline, M. L., & Hussein, Z. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1683 · Cited by 23
May, T., Holloway, K. R., Buhociu, M., & Hills, R. (2020) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102823 · Cited by 21
‘Z-trip’? A Comprehensive Overview and a Case-series of Zolpidem Misuse
Orsolini, L., Chiappini, S., Grandinetti, P., Bruschi, A., Testa, R., Provenzano, A., Berardis, D. D., & Volpe, U. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.367 · Cited by 31
“After assessing the potential of abuse, dependence, and withdrawal of Z-drugs, through the analysis of datasets of adverse drug reactions provided by the European Medicines Agency, it has been demonstrated that zolpidem is more frequently involved in both misuse/abuse and withdrawal issues [33].”
BackgroundSelf-citationPerelló, M. F., Rio-Aigé, K., Guayta-Escolies, R., Gascón, P., Rius, P., Jambrina, A. M., Bagaría, G., Armelles, M., Pérez-Cano, F. J., & Rabanal, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18157818 · Cited by 21
“This fact could reflect that the utilisation of benzodiazepines and z-drugs has substantially increased with the ageing of the population, and they are most often prescribed in general practice, and it is well described that they are addictive and often used in larger doses and for a longer time than recommended [29,3…”
BackgroundComing Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Schifano, F. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507897 · Cited by 18
Self-citationMolecular basis for anti-insomnia drug design from structure of lemborexant-bound orexin 2 receptor
Asada, H., Im, D., Hotta, Y., Yasuda, S., Murata, T., Suno, R., & Iwata, S. (2022) · Structure · doi:10.1016/j.str.2022.11.001 · Cited by 23
Coteur, K., Mamouris, P., Vaes, B., Nuland, M. V., Matheï, C., & Schoenmakers, B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1014734 · Cited by 24
“Since they cause the same adverse side effects as benzodiazepines when used in the long term, including their potential for recreational abuse (65), future campaigns about BZRA discontinuation should explicitly mention and possibly target z-drugs prescribing behavior.”
BackgroundDependence on hypnotics: a comparative study between chronic users of benzodiazepines and Z-drugs
Curado, D. F., de Barros, V. V., Noto, A. R., & Opaleye, E. S. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-1651 · Cited by 24
Cadogan, C. A., Bradley, C., & Bennett, K. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03063-z · Cited by 17
“Z-drugs are a comparatively newer group of non-benzodiazepine hypnotics with similar risk profiles to benzodiazepines [2, 3].”
BackgroundCaillet, P., Rousselet, M., Gérardin, M., Jolliet, P., & Victorri‐Vigneau, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228495 · Cited by 28
Jouanjus, É., Micallef, J., Mallaret, M., & Lapeyre‐Mestre, M. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz033 · Cited by 18
Soeiro, T., Pradel, V., Lapeyre‐Mestre, M., & Micallef, J. (2023) · Addiction · doi:10.1111/add.16261 · Cited by 19
Papazisis, G., Spachos, D., Siafis, S., Pandria, N., Deligianni, E., Tsakiridis, I. G., & Goulas, A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.640264 · Cited by 16
Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep?
Schreiber, S., & Pick, C. G. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109501 · Cited by 16
Zolpidem high-dose abuse: what about the liver? Results from a series of 107 patients
Lugoboni, F., Mirijello, A., Morbioli, L., Faccini, M., Casari, R., Cosmo, S. D., Gasbarrini, A., & Addolorato, G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1628216 · Cited by 20
Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant
Asakura, S., Shiotani, M., Gauvin, D. V., Fujiwara, A., Ueno, T., Bower, N., Beuckmann, C. T., & Moline, M. L. (2021) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2021.105053 · Cited by 14
Ramos, C., Guirguis, A., Smeeton, N., Zaman, H., Felice, A. M., Bancroft, S., Gittins, R., Hawksworth, G., Corkery, J., & Schifano, F. (2020) · Brain Sciences · doi:10.3390/brainsci10030142 · Cited by 14
“%) assessed themselves as ‘not confident’ about the provision of advice regarding the safe management of ADRs resulting from NPS use.”
BackgroundInfluentialSelf-citationGarel, N., Greenway, K. T., Dinh-Williams, L.-A. L., Thibault-Levesque, J., Jutras-Aswad, D., Turecki, G., Rej, S., & Richard-Devantoy, S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01689-y · Cited by 13
“Deprescribing BZDRs may therefore yield benefits, in appropriate patients, but is often clinically challenging due to common and distressing withdrawal symptoms like rebound anxiety, insomnia, and depressive symptoms including increased suicidality [6, 7, 10, 11].”
BackgroundSchifano, N., Capogrosso, P., Boeri, L., Fallara, G., Chiappini, S., Rewhorn, M., Çakır, Ö. O., Harvey, H., Castiglione, F., Alnajjar, H. M., et al. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-022-00568-2 · Cited by 13
“The higher signal here identified from the EV vs. the FAERS database may reflect a different perception of the possible side effects of finasteride; a different market availability of the molecule; and a different extent of its use in the EEA vs. the U.S., respectively.”
InfluentialSelf-citationSedative drug-use in Denmark, 2000 to 2019: a nationwide drug utilization study
Rosenqvist, T. W., Osler, M., Wium‐Andersen, M. K., & Wium‐Andersen, I. K. (2022) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-022-02409-5 · Cited by 14
“Z-drugs had less daytime impairment and were assumed to be less addictive than benzodiazepines [5, 6], but over the years the same concerns regarding tolerance, abuse, and addiction arose [4, 7] and recent studies have documented the risk of long-term use of both benzodiazepines and Z-drugs [8, 9] including risk of in…”
BackgroundKozlov, O., Záhoráková, D., & Gondová, T. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113549 · Cited by 11
Żełabowski, K., Pichowicz, W., Skowron, I., Szwach, J., Biedka, K., Wesołowski, M., Błaszczyk, K., Ziobro, O., Petrov, W., Kukuła‐Koch, W., et al. (2025) · Molecules · doi:10.3390/molecules30183814 · Cited by 20
“…hypnotics, including benzodiazepines (e.g., diazepam, lo-razepam, temazepam) and Z-drugs (e.g., zolpidem, zopiklon) [17] are associated with a significant risk of dependence [18], long-term deterioration in sleep quality [19] and the emergence of withdrawal symptoms upon discontinuation [20].”
Progress in GABAA receptor agonists for insomnia disorder
Wang, W., Fu, W., Zhu, H., Ma, J., Zhang, J., & Qi, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1432726 · Cited by 17
Fatal Intoxications with Zopiclone—A Cause for Concern?
Tralla, L., Gustavsson, S., Söderberg, C., Jönsson, A. K., & Kugelberg, F. C. (2024) · Drug Safety · doi:10.1007/s40264-024-01424-6 · Cited by 13
“However, more recent data show that zopiclone has the potential to cause dependence and withdrawal [11, 12] and is involved in cases of driving under the influence [13, 14], motor vehicle crashes [3], and overdoses [3, 12, 15].”
BackgroundIsomura, K., Wang, X., Chang, Z., Hellner, C., Hasselström, J., Ekheden, I. G., Jayaram‐Lindström, N., Lichtenstein, P., D'Onofrio, B. M., Mataix‐Cols, D., et al. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03515-2 · Cited by 22
Zolpidem as a high risk factor for elderly suicide in South Korea
Kim, E., Lee, J. H., & Lee, D. H. (2020) · Archives of Suicide Research · doi:10.1080/13811118.2020.1838369 · Cited by 12
The putative effects of orexin receptor antagonists on pain and sleep in humans: A systematic review
Babiloni, A. H., Sangalli, L., Puertas, F. J., Morin, C. M., Lavigne, G. J., & Fabbro, C. D. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106633 · Cited by 10
Glancy, M., Palmateer, N. E., Yeung, A., Hickman, M., Macleod, J., Bishop, J., Barnsdale, L. R., Trayner, K. M. A., Priyadarshi, S., Wallace, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116028 · Cited by 14
“…to gabapentinoids and other commonly prescribed medications such as benzodiazepines often taken in combination with opioids and other substances (Schifano et al., 2019; McHugh et al., 2023) (although this is likely to vary by region, for example, in the United States where Z-drugs are…”
BackgroundKim, S.-H., & Lim, J.-H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031754 · Cited by 10
“Although, Z-drugs are sold as alternatives to benzodiazepines, they have been frequently associated with both withdrawal issues and misuse/abuse [23].”
Backgroundde Campos, E. G., Martinis, E. C. P. D., & Martinis, B. S. D. (2021) · Brazilian Journal of Analytical Chemistry · doi:10.30744/brjac.2179-3425.rv-19-2021 · Cited by 10
Patki, M., Palekar, S., Nukala, P. K., Vartak, R., & Patel, K. R. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01879-7 · Cited by 8
Drug prescriptions preceding opioid-related deaths–a register study in forensic autopsy patients
Walde, J., Andersson, L., Johnson, B., & Håkansson, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285583 · Cited by 9
[Appropriate Use and Abuse of Sedative-Hypnotic Drugs].
Zheng, J.-W., Meng, S., Liu, W.-Y., Chang, X., & Shi, J. (2023) · 四川大学学报:医学版 · doi:10.12182/20230260302 · Cited by 12
Jobski, K., Bantel, C., & Hoffmann, F. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03431-x · Cited by 7
“The database has been used previously to examine abuse and dependence, e.g. with respect to fentanyl [13] or Z-drugs [15].”
BackgroundOccurrence of involuntary movements after prolonged misuse of zolpidem: a case report
Ricciardulli, S., Lattanzi, L., Barbuti, M., Ceravolo, R., & Perugi, G. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000443 · Cited by 10
González‐Chica, D. A., Begum, M., Bernardo, C., Hoon, E. A., Sweetman, A., & Stocks, N. P. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13561 · Cited by 8
Jahnsen, J. A., Widnes, S. F., & Schjøtt, J. D. (2021) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s296515 · Cited by 10
“Despite extensive studies before gaining market authorization, problematic safety issues, including misuse and dependency, have been discovered post-marketing for drugs that effectively treat insomnia.(14,15) Consequently, there is in clinical practice a need for effective pharmacological treatment of insomnia without…”
BackgroundDepression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Sinclair, J., Kalk, N. J., Kaar, S. J., Agabio, R., Arunogiri, S., Bisaga, A. M., Chesney, E., Daly, C., Dewhurst, J., Freeman, T. P., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251399593 · Cited by 16
“Tolerance, withdrawal, dependence and deaths related to toxicity have been reported, particularly in polysubstance-use populations (Aquizerate et al., 2024; Schifano et al., 2019; Tralla et al., 2024).”
Cicala, G., Barbieri, M. A., Russo, G., Salvo, F., & Spina, E. (2024) · Pharmaceuticals · doi:10.3390/ph17030342 · Cited by 12
“In addition to that, therapy discontinuation can often lead to protracted withdrawal symptoms that persist for several months [10,11].”
BackgroundMethodInfluentialBrief Intervention as a Method to Reduce Z-Hypnotic Use by Older Adults: Feasibility Case Series
Bjelkarøy, M. T., Simonsen, T. B., Siddiqui, T. G., Halset, S., Cheng, S., Grambaitė, R., Benth, J. Š., Gerwing, J., Kristoffersen, E. S., & Lundqvist, C. (2024) · JMIR Formative Research · doi:10.2196/51862 · Cited by 6
“Even so, these drugs are associated with adverse events and dependence [9,10].”
BackgroundPrescribing Z-drugs in Greece: an analysis of the national prescription database from 2018 to 2021
Siafis, S., Fountoulakis, K. Ν., Fragkidis, V., & Papazisis, G. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04793-x · Cited by 28
“The prescription patterns of Z-drugs are particularly of great importance, as these medications were initially marketed and perceived as safe alternatives to benzodiazepines, yet they can also result in abuse and dependence, among other side-effects [4, 6].”
BackgroundMedarević, A. (2022) · Glasnik javnog zdravlja · doi:10.5937/serbjph2202126m · Cited by 4
“The growth in Z-hypnotics use is associated with the high expectations that accompanied these drugs in the first years of use, when they were considered more effective and safe than the widespread benzodiazepines [30].”
BackgroundGuo-Zhong, M., Sun, L., Qie, Z., He, J., & Cui, F. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s298552 · Cited by 6
“These z-drugs were initially perceived to be much safer than traditional benzodiazepine but associated with the same risks for dependence and withdrawal.(47) In the present study, we also found that z-drugs are a risk factor for both short-term and prolonged use.”
BackgroundNarisawa, H., Inoue, Y., Kobayashi, M., Okajima, I., Kikuchi, T., Kagimura, T., Matsui, K., Inada, K., & Mishima, K. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113900 · Cited by 9
Curado, D. F., de Barros, V. V., Opaleye, E. S., & Noto, A. R. (2020) · Trends in Psychiatry and Psychotherapy · doi:10.1590/2237-6089-2019-0049 · Cited by 6
HOROWSKI, R. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02209-8 · Cited by 10
“The claim that they have a lower risk for inducing dependence has not been substantiated (Gunja 2013; Hoffmann and Glaeske 2014; Schiffano et al. 2019).”
BackgroundEl‐Deen, A. K., & Hussain, C. M. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116821 · Cited by 5
Nicola, M. D., Pepe, M., Bonomo, L., Milintenda, M., Panaccione, I., Brugnoli, R., & Sani, G. (2025) · Pharmaceuticals · doi:10.3390/ph18030378 · Cited by 6
“…of benzodiazepines diminishes after one to two weeks of continuous intake, promoting tolerance and dependence [9], while chronic use can result in withdrawal symptoms upon discontinuation including rebound insomnia, anxiety, and irri-tability, which further complicate clinical management [10,11].”
Zolpidem-related euphoria, addiction and detoxification: A case report and review of the literature
Xie, F., Liu, B., Yang, L., Huang, J., Li, B., & Li, Y. (2024) · Medicine · doi:10.1097/md.0000000000040280 · Cited by 7
“[1] Zolpidem dependence occurs when an individual long-term misuses the medication, resulting in drug tolerance and withdrawal symptoms, along with impaired function.”
BackgroundZolpidem-triggered atrial fibrillation in a patient with cardiomyopathy: a case report
Li, X., & Jin, Y. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04016-5 · Cited by 9
“It has adverse events, including falls and subsequent fractures [2, 3], neuropsychological adverse effects such as parasomnias, amnesia, hallucinations, and suicidality [4, 5], as well as abuse, dependence, and withdrawal [6].”
BackgroundDurand, L., Keenan, E., O’Reilly, D., Bennett, K., O’Hara, A., & Cousins, G. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05195-9 · Cited by 8
“Z-drugs, a comparatively newer group of non-benzo-diazepine hypnotic agents, licensed for use in the 1990s for insomnia, have a similar risk profile to benzodiaz-epines [11, 12].”
BackgroundGuan, R., Pan, L., Yu, Z., Liu, Z., Shi, Q., & Li, J. (2023) · Medicine · doi:10.1097/md.0000000000032645 · Cited by 5
“[12,13] Due to the limitations of pharmacotherapy, including potential dependence and tolerance under long-term use,[14,15] and the recognition of excessive anxiety factors in the insomnia trajectory, non-pharmacological approaches have received increasing attention in the past decade.”
BackgroundDependence on zopiclone: a case report
Guo, N., & Zhou, X. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1592065 · Cited by 4
“Current regulatory focus on Z-drugs primarily targets zolpidem, which, according to the World Health Organization (WHO), has an abuse and dependency pro fi le similar to BDZs.”
InfluentialCarvalho, F., Tonon, A. C., Hidalgo, M. P., Martins Costa, M., & Mengue, S. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405838 · Cited by 4
Altered Mental Status and Delirium in Pediatric Patients
Bieber, E. D., Smith, H. A. B., Fuchs, D. C., & Gangopadhyay, M. (2024) · Seminars in Neurology · doi:10.1055/s-0044-1791227 · Cited by 7
“46,47 ■ Popularized on social media platforms, the “ Benadryl Challenge ” has resulted in several patients presenting with hyperactive delirium due to anticholinergic toxicity.”
Burmester, S., Krüger, C., Franck, J., Lindberg, M. H., & Westman, J. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209508 · Cited by 7
“Many individuals using benzodiazepines experience short-term relief of symptoms; however, long-term use is associated with adverse outcomes (Fenton et al., 2010; Peng et al., 2022; Schifano et al., 2019).”
Medicalization of Sport? A Mixed-Method Study on the Use of Medications in Elite Ice Hockey
Christensen, S. K., Gjelstad, A., Björnsdóttir, I., et al. (2024) · Sports · doi:10.3390/sports12010019 · Cited by 4
“This concern extends beyond the use of local anesthetics to include adverse effects of oral anesthetics [6] and addiction to hypnotics [31].”
BackgroundBarbosa, B. A. D. S., da Costa, P. A., da Silva, E. V., et al. (2023) · Hygeia - Revista Brasileira de Geografia Médica e da Saúde · doi:10.14393/hygeia1968623 · Cited by 4
A Review of Drug Abuse, Misuse, and Related Laboratory Challenges
Ranjkeshzadeh, H., Sepahi, S., Zare‐Zardini, H., Yazdi, M. E. T., Ghorani‐Azam, A., & Jafari, A. (2023) · Current Drug Safety · doi:10.2174/0115748863266621231023112044 · Cited by 7
Hartmayer, L. T., Hoffmann, F., Bachmann, C., & Jobski, K. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000451 · Cited by 5
“Therefore, it has already been used to examine abuse, dependence and withdrawal of other substances, for example, Z-drugs (Schifano et al., 2019).”
Libman, H., Zhou, E. S., Heckman, E. J., & Smetana, G. W. (2022) · Annals of Internal Medicine · doi:10.7326/m22-2817 · Cited by 4
Campagnari, S., Zamboni, L., Fusina, F., Casari, R., & Lugoboni, F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1033061 · Cited by 5
Predicting Hypnotic Use among Insomnia Patients with the Theory of Planned Behavior and Craving
Yang, C., Lai, Y.-S., Huang, Y., Huang, Y.-C., & Lee, H. (2022) · Behavioral Sciences · doi:10.3390/bs12070209 · Cited by 4
“Although non-benzodiazepine benzodiazepine receptor agonists (BzRAs) were claimed to be safer alternatives to BZDs, concerns about abuse, dependence, and withdrawal have increased over the past decade [16].”
BackgroundOueini, R., Goodin, A. J., Hincapie‐Castillo, J. M., & Vouri, S. M. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.10.020 · Cited by 4
Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy
Larrivee, D. C. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.91536 · Cited by 5
Bazmi, S., Pourmontaseri, H., Shahraki, S. F. M., Pourmontaseri, A. R., Askari, A., Bagheri, P., Homayounfar, R., Farjam, M., Dehghan, A., Fakhraei, B., et al. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00998-w · Cited by 5
Ariza-Salamanca, D. F., Venegas, M., Parejo, K., Galeano, S. A., Echeverry, J., & Calderón‐Ospina, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103297 · Cited by 6
“There is a similar preoccupying scenario as there is substantial evidence demonstrating the addictive potential of benzo-diazepines and Z-drugs [55,56].”
Melatonin: A Review of the Evidence for Use in Hospital Settings
Adattini, J. A., Wills, C., & Martin, J. H. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70059 · Cited by 6
Leal, G. N., Studart, I., Figueiredo, C. P. M., Santi, T. D., Suen, P. J. C., Brasiliano, S., Hochgraf, P. B., & Bacchi, P. S. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1456148 · Cited by 7
Tsay, W.-Y., Chen, L., Wu, S., Hsiao, P., Ting, T., Yen, C., Chang, S., Li, C., Yang, H., Yen, C.-F., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-20778-1 · Cited by 5
Schindler, N. J., Zepel, L., Maciejewski, M. L., Hastings, S. N., Clark, A. G., Dublin, S., Albertson-Junkans, L. H., & Pavon, J. M. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01144-7 · Cited by 6
Metadata
- Authors
- Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A.
- Affiliations
- University of Hertfordshire (GB)
- Corresponding author
- Chiappini, Stefania
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-02-05
- Volume
- 22
- Issue
- 4
- Pages
- 270-277
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6441128
- OpenAlex
- W2914189181
- Cited by
- 194
- References
- 51
- Citations by year
- 2026: 26 · 2025: 23 · 2024: 29 · 2023: 35 · 2022: 24 · 2021: 31 · 2020: 19 · 2019: 6
- FWCI
- 14.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion, cc-by-nc)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
- Funders
- EMA
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- Z-drugs, zaleplon, zolpidem, zopiclone, drug abuse, drug addiction, withdrawal, misuse, drug overdose, adverse drug reactions, pharmacovigilance, benzodiazepine alternatives, EudraVigilance, proportional reporting ratio
- MeSH terms
- Drug Misuse, Zolpidem, Acetamides, Adolescent, Adult, Europe, Female, Humans, Hypnotics and Sedatives, Male, Middle Aged, Piperazines, Pyrimidines, Databases, Factual, Substance-Related Disorders, Azabicyclo Compounds, Young Adult, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.